nobiletin has been researched along with Triple Negative Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Eckel-Mahan, K; Ji, Z; Kang, JM; Kim, E; Kim, JA; Kim, YJ; Lee, HK; Ono, K; Paudel, KR; Smith, JA; Wirianto, M; Yoo, JY; Yoo, SH; Zhou, X | 1 |
| Borah, N; Gunawardana, S; McDonnell, S; Torres, H; Van Slambrouck, S | 1 |
2 other study(ies) available for nobiletin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
ROR activation by Nobiletin enhances antitumor efficacy via suppression of IκB/NF-κB signaling in triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Flavones; Humans; I-kappa B Kinase; Mice; NF-kappa B; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2022 |
5,6,7,3',4',5'-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Female; Flavones; Humans; MAP Kinase Signaling System; Proto-Oncogene Proteins c-akt; Triple Negative Breast Neoplasms | 2017 |